Cells and prions: A license to replicate by Nuvolone, M et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2009
Cells and prions: A license to replicate
Nuvolone, M; Aguzzi, A; Heikenwalder, M
Nuvolone, M; Aguzzi, A; Heikenwalder, M (2009). Cells and prions: A license to replicate. FEBS Letters,
583(16):2674-2684 .
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
FEBS Letters 2009, 583(16):2674-2684 .
Nuvolone, M; Aguzzi, A; Heikenwalder, M (2009). Cells and prions: A license to replicate. FEBS Letters,
583(16):2674-2684 .
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
FEBS Letters 2009, 583(16):2674-2684 .
Cells and prions: a license to replicate. 
 
Mario Nuvolone1,2, Adriano Aguzzi1 and Mathias Heikenwalder1. 
 
1Department of Pathology, Institutes of Neuropathology, University Hospital Zurich, CH 8091, 
Switzerland. 
2Amylod Center, Fondazione IRCCS Policlinico San Matteo, Department of Internal Medicine, 
University of Pavia, Pavia, Italy. 
 
 
 
 
Correspondence: Mathias Heikenwalder 
   Institute of Neuropathology 
   University Hospital Zurich 
   Schmelzbergstrasse 12 
   CH-8091 Zurich, Switzerland 
   Phone: +41 (44) 255-2106 
   FAX: +41 (44) 255-4402 
   E-mail: mathias.heikenwaelder@usz.ch  
 
 
 
 
 
Keywords:  
Prion replication competence;  
follicular dendritic cells (FDCs);  
stromal inflammatory cells;  
neuroinvasion;  
mesenchymal progenitor cells (MPCs). 
 2
Abstract 
Prion diseases are neurodegenerative, infectious disorders characterized by the aggregation of 
a misfolded isoform of the cellular prion protein (PrPC). The infectious agent - termed prion - 
is mainly composed of misfolded PrPSc. In addition to the central nervous system prions can 
colonize secondary lymphoid organs and inflammatory foci. Follicular dendritic cells are 
important extraneural sites of prion replication. However, recent data point to a broader range 
of cell types that can replicate prions. Here, we review the state of the art in regards to 
peripheral prion replication, neuroinvasion and the determinants of prion replication 
competence. 
      
Prion diseases: Infectious neurodegenerative disorders in humans and animals 
Prion diseases, also designated as transmissible spongiform encephalopathies (TSEs), are 
infectious and invariably fatal neurodegenerative disorders affecting humans and animals [1-
3]. These include kuru, Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker 
disease (GSS) and fatal familial insomnia (FFI) in humans, as well as scrapie of sheep and 
goats, bovine spongiform encephalopathy (BSE) or “mad cow disease” of cattle and chronic 
wasting disease (CWD) of deer and elk [1-3].   
The last century has witnessed a tremendous series of tragic episodes related to prion diseases 
[2]. Until the middle of the twentieth century kuru decimated Papua New Guinea aborigines 
devoted to ritualistic consumption of central nervous system (CNS)-derived tissues [4]. The 
employment of prion-contaminated gonadotropins, corneal transplantations, dura mater grafts 
and surgical instruments has resulted in more than 250 cases of iatrogenic CJD in the 1970s 
with drastic implications for clinical practice [2]. Starting from 1986, the epidemic of BSE 
has affected more than 280’000 cattle, provoking a food crisis with unprecedented, worldwide 
economic consequences. Transmission of the BSE agent to humans has been regarded as the 
cause of a new clinico-pathological entity, termed variant CJD (vCJD), which was first 
described in 1996 [5,6] and has so far caused death in 212 individuals (http://www.cjd. 
ed.ac.uk/vcjdworld.htm). The rising incidence of vCJD in the late 1990s and the possibility 
that millions of people have been exposed to BSE-contaminated meat have evoked fears of an 
upcoming pandemic. 
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The versatile prion 
The beginning of the present century has brought the encouraging news of a stabilizing or 
subsiding incidence of vCJD, but novel alarming facts are indicating that prions are much 
more versatile than previously thought. The occurrence of horizontal transmission of vCJD by 
blood transfusions [7,8] has indicated that vCJD prions can recycle among subclinical 
humans. This trouble was not necessarily predicted by mouse models [9,10] and poses a new, 
worldwide challenge for health authorities in terms of donor deferral criteria and blood quality 
surveillance, while a specific and sensitive test for the detection of prions in human blood is 
still pending [11]. Only recently, the Health Protection Agency of the United Kingdom has 
reported a case of a hemophilic patient who, most likely, has acquired vCJD prions through 
Factor VIII preparation derived from plasma donated by a “preclinical” vCJD patient 
(http://www.hpa.org.uk). Moreover, recent reports from work with kuru patients in New 
Guinea indicate that heterozygosity at polymorphic codon 129 (129M/V) of PRNP, the gene 
encoding the human prion protein, could lead to incubation periods exceeding 50 years [12].  
These findings demonstrate that we need to learn more about horizontal prion transmission in 
humans, how to detect subclinical carriers and if or how those can become a potential risk for 
public health. Future observations will have to show whether any of the above mentioned will 
impact on the epidemiology of vCJD. 
Moreover, a recrudescence of scrapie outbreaks among European sheep flocks has been 
described in the last years and new cases of BSE and vCJD have been reported in countries 
and continents previously deemed prion-free [13]. In this regard it is important to mention that 
is unknown by today whether scrapie prions can pose a potential health risk to humans. 
In addition, an atypical BSE strain - called bovine amyloidotic spongiform encephalopathy 
(BASE) - has been identified in different countries displaying biochemical properties similar 
to a subgroup of sporadic CJD (sCJD) [14]. These data questioned whether a temporarily 
defined increase in sCJD cases (e.g. in Switzerland) was a result of BASE transmission to 
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humans [15]. Furthermore, the spread of CWD of cervids in North America and the potential 
dietary-exposure of millions of individuals to prion-contaminated venison have raised the still 
unsolved question of human susceptibility to CWD prions [16].  
Recent inventions and refinements in the technologies for detection of the disease-associated 
prion protein have significantly extended and shifted our knowledge about prion tropism [17]. 
The general belief that sCJD prions are rather confined to the CNS when compared to vCJD 
prions, which also colonize peripheral organs, was first shaken by investigating extraneural 
organs of sCJD patients using novel or advanced techniques [18-20]. Disease-associated prion 
proteins have been detected in the olfactory epithelium [21], as well as in spleen and muscle 
tissue of sCJD victims [19]. Moreover, prion infectivity was demonstrated in saliva, milk, 
blood and muscles of TSE affected individuals [22-25] and, as substantiated below, in 
chronically inflamed organs (e.g. mammary gland, liver, kidney) [26-28]. Scrapie infection in 
nephritic mice leads to urinary prion secretion (also termed prionuria), even at subclinical 
stage [29]. Further, moderate intestinal inflammation at the time of prion exposure increases 
the susceptibility to orally administered prions [30]. Taken together, these observations 
indicate that environmental factors (e.g. inflammation) can change the prion tropism to organs 
hitherto believed prion-free [17,28,31]. Nevertheless, peripheral prion accumulation was 
reported to occur also in excretory organs and body fluids under non-inflammatory 
conditions, however to much less degree [25,32]. In summary, these data question the current 
risk assessment of high-infectivity organs in humans and animals, so far mainly including the 
CNS and the lymphoreticular system (LRS). 
Although prion diseases have always been regarded as a “sui generis” class of infectious 
maladies, recent findings have challenged this notion. Data from murine models of 
Alzheimer’s disease indicate that exogenous A amyloid is capable of inducing cerebral A 
amyloidosis with disease phenotypes that are governed by both the host and the inoculum, 
features reminiscent of prion strains [33]. These findings are fascinating and support the 
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hypothesis that pathogenic mechanisms operating in prion diseases might be shared by other 
neurodegenerative disorders [34,35].  
Despite substantial progress in our understanding of prion pathogenesis, a number of crucial 
questions still remain unanswered. These include the exact nature of the infectious agent, the 
cellular and molecular mechanisms of central and peripheral prion replication, the defining 
traits of prion strains, the determinants of prion toxicity, the routes of horizontal transmission 
and the mechanistic basis of species barrier.  
Here, we review the current state of art in prion biology and prion immunology. In addition 
we examine the currently available tools to detect prions and summarize the immunological 
interventional strategies against prion diseases explored so far. 
 
The infectious agent 
The etiologic agent of TSEs is termed prion (proteinaceous infectious only) and displays 
unconventional properties, such as resistance to UV irradiation, exposure to high pressures or 
temperatures and formaldehyde treatment. According to the protein-only hypothesis, it is 
devoid of informational nucleic acid and coincides with scrapie prion protein (PrPSc), an 
abnormal isoform of PrPC, which is capable of converting PrPC into a likeliness of itself [36].  
Despite considerable efforts, no posttranslational chemical modifications that might 
discriminate between PrPC and PrPSc were found, indicating that solely conformational 
changes distinguish the two PrP isoforms [37]. The fine structure of PrPC is known at the 
atomic level [38]. On the other hand, no high-resolution structure is available for PrPSc, but 
limited data from low-resolution structural methods are compatible with a significantly 
different conformation of PrPSc with respect to PrPC [39,40]. 
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Prion strains 
The prion strains phenomenon adds a further level of complexity to the question of protein 
structure [41]. Prion strains are TSE isolates or sources of prion infectivity that, upon 
inoculation into genetically identical hosts, cause disease with consistent characteristics, 
including incubation time, lesion profiles within the CNS and even tropism for extracerebral 
cell types [41-43]. To accommodate the existence of different prion strains within the frame 
of the protein-only hypothesis, one should postulate that PrPSc must exist in various distinct 
pathological conformations, each one able to impart its own conformation onto PrPC, thus 
culminating in distinct disease characteristics [41,44]. 
 Detection of prions: From mice to test-tubes 
In this context, detection of bona fide prions is achievable only through determination of prion 
infectivity. This is classically performed by bioassay in which serial dilutions of the test 
material are inoculated into experimental animals, and the dilution at which 50% of the 
animals contract the disease (termed ID50) is determined [45]. However, this system suffers 
from inaccuracy, is time-consuming and is limited by the requirement of scores of animals.  
These limitations are partly overcome by a recently developed assay based on prion-
susceptible cell lines, termed scrapie cell endpoint assay [46]. This method combines the 
sensitivity and intrinsic biological validity of the bioassay (i.e. direct measurement of 
infectivity) with the speed, convenience and amenability to high-throughput automation of an 
in vitro system. Extension of the susceptibility of neuronal cell lines used in this assay, 
currently restricted to various murine prion strains, could pave the way for a sensitive test to 
detect prion infectivity, with both medical and veterinarian applications. 
As an alternative to prion infectivity assessment, various biochemical or biophysical 
peculiarities of PrPSc, presumably stemming from its differential conformation with respect to 
PrPC, can be operationally used as surrogate markers for prion infection. 
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The first reliable surrogate marker of prion infectivity is its partial resistance against 
proteolytic degradation. Incubation with 50 μg/mL of proteinase K (PK) at 37°C for 2 hours 
does not degrade the carboxyl-proximal domain of the disease-associated prion protein, nor 
decrease the infectious titer of the prion preparation [47]. More than 25 years after it was first 
described, the detection of PK-resistant prion protein still remains the gold standard for the 
biochemical diagnosis of prion diseases and forms the basis of all the marketed BSE tests.  
Biochemical detection of PK-resistant prion protein can be performed in combination with 
histological techniques. In particular, blotting either paraffin-embedded tissue (PET blots) 
[48] or cryosections (histoblots) [49] onto nitrocellulose membrane, followed by digestion 
with PK and decoration with anti-PrP antibodies enables the detection of PK-resistant prion 
protein in situ, thus providing precious information about topographic distribution of the 
pathologic protein in disease tissues.  
PK-resistant prion protein is not always easily detectable in tissues or body fluids from 
affected hosts. In 2001 a significant step towards a more sensitive method of detection of 
PrPSc has been achieved [18]. Selective precipitation of PrPSc from tissue homogenates with 
sodium phosphotungstic acid results in the concentration of PrPSc from large volumes of test 
material. Combination of this preparative step with immunoblot detection results in increased 
sensitivity of Western blot analysis by up to three orders of magnitude and has been 
extensively exploited to detect PrPSc in extraneural sites of TSE victims [18,19]. In the same 
year another milestone for sensitive detection of the pathological prion protein is represented 
by the so called protein misfolding cyclic amplification (PMCA) [50]. Analogously to a PCR 
reaction, PMCA generates PrPSc from monomeric substrates and a small amount of template 
PrPSc. Amplification of PrPSc is achieved through cycles of sonication, which disrupts the 
PrPSc aggregates, and elongation, that entails incubation with the monomeric substrate which 
is recruited by the misfolded prion protein, and is accompanied by an increase in prion 
infectivity. This technology succeeded to detect amplifiable PrPSc in blood of prion-infected 
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hamsters in the presymptomatic phase of the disease [51], suggesting that PMCA might prove 
to become a sensitive non-invasive method for early diagnosis of prion diseases. However, the 
fact that PMCA can generate de novo prions from non-infectious material [52] emphasizes 
that the technique may be prone to false positives, thus questioning its usefulness as a 
diagnostic tool [11]. Besides this limitation, PMCA could also prove instrumental in 
expanding our understanding of prion replication mechanisms [11]. 
An additional strategy to detect the disease-associated protein relies on the assumption that, 
upon conversion to PrPSc, at least some epitopes of PrPC are buried in the aggregates. The 
measurement of the differential binding of anti-PrP antibodies to native vs. denaturated prion 
protein, which constitutes the basis of the conformation-dependent immunoassay, provides a 
sensitive assay to detect PrPSc and a good tool to investigate the existence of conformational 
differences between distinct strains of prions [53]. 
 
The physiological function of PrPC: PrPC and the CNS 
PrPC is tethered to the external surface of cells by a glycosyl phosphatidyl inositol (GPI) 
anchor and is enriched in detergent-resistant microdomains of cellular membrane termed lipid 
rafts. It undergoes facultative N-linked glycosylation at two sites, which results in un-, mono- 
or diglycosylated moieties. 
The expression pattern of PrPC is broad, developmentally regulated and includes the nervous 
system (with high PrPC levels in synaptic membranes of neurons and on astrocytes), 
secondary lymphoid organs, skeletal muscle, kidney and heart. PrPC is highly conserved 
among mammals, and paralogues thereof are present in birds, reptiles, amphibians and 
possibly in fish. No naturally occurring Prnp-null alleles have ever been observed in any 
mammalian species. These observations suggest a broad and conserved function for the 
protein [2]. 
 8
Despite intensive investigations and the availability of Prnp0/0 mice since 1992, the 
physiological function of PrPC has not been clearly identified. Prnp ablation per se does not 
elicit neurodegeneration [54], even when induced postnatally [55]. Therefore, prion pathology 
is unlikely to be the result of a loss of PrPC function. However, PrPSc conversion might alter 
the physiological function of PrPC and confer a toxic dominant function. This could include 
altered signal transduction, enzymatic activity, and change in substrate specificity or protein 
binding properties. In this scenario, elucidating the physiological function of PrPC may be 
instrumental to deciphering the mechanisms of prion pathogenesis and eventually to devising 
tailored interventional strategies. A non exhaustive list of putative functions of PrPC includes 
signal transduction, regulation of circadian rhythm, copper binding, proliferation of neural 
precursors, processing of sensory information by the olfactory system, cellular iron uptake 
and transport, pro-apoptotic or anti-apoptotic function and others [56]. 
 
PrPC, prion replication and neurodegeneration  
The only universally acknowledged function of PrPC is to replicate prions and mediate their 
toxicity: Prnp0/0 mice are resistant to prion infection [54]. Brain tissue devoid of PrPC is not 
damaged by exogenous PrPSc, as demonstrated by refined brain grafting experiments of PrPC 
overexpressing brain tissue into Prnp0/0 brains [57]. Surprisingly, depleting endogenous 
neuronal PrPC in prion-infected mice reverses early spongiosis and prevents neuronal loss and 
progression to clinical disease, despite the accumulation of extraneuronal PrPSc to levels 
normally found in terminally sick wild-type (wt) animals [55]. Moreover, scrapie-infected 
transgenic mice exclusively expressing a monomeric, soluble secreted form of PrPC that lacks 
the GPI anchor do not develop overt prion disease, while PrPSc accumulate in their brains in 
form of amyloid plaques [58]. Collectively, these findings indicate that PrPSc is per se 
innocuous and that prion replication avails itself of membrane-bound PrPC on neurons to elicit 
neurotoxicity [59].  
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Recently, Strittmatter and colleagues have provided evidence that PrPC is a high-affinity cell-
surface receptor for soluble synthetic A oligomers on neurons and might play a central role 
in the pathophysiological process of Alzheimer’s disease [60]. This finding is intriguing and 
future investigations will have to elucidate whether PrPC binds to naturally occurring A 
oligomers in vivo. In addition, the clinical relevance and the therapeutic implications of this 
discovery have to be clarified [61]. 
 
PrPC and the immune system 
With regard to the immune system, PrPC is expressed in T and B lymphocytes, natural killer 
(NK) cells, platelets, erythrocytes, monocytes, dendritic cells (DCs) and follicular dendritic 
cells (FDCs), albeit with significant differences across species and among states of maturation 
and subsets of immune cells [17]. PrPC has been implicated in T lymphocyte development, 
activation and in the interaction of T lymphocytes and DCs [62,63]. Overexpression of PrPC 
in transgenic mice has been shown to alter T cell development in the thymus via local 
generation of an antioxidant milieu [64], but recent work of Zabel et al. has indicated that this 
phenotype might be caused by an insertional mutation of the Prnp transgene [65].  
Genetic or pharmacological ablation or PrPC in macrophages results in an increased rate of 
phagocytosis of various apoptotic cells, indicating that PrPC is a negative regulator of 
phagocytosis [66]. PrPC has also been shown to promote the swimming internalization of 
Brucella abortus into macrophages through the interaction with bacterial Hsp60 [67,68]. 
However, these data are highly controversial and one publication could not reproduce the 
finding by Watarai et al. [69]. Furthermore, another study indicated that PrPC is expressed on 
the surface of hematopoietic stem cells and supports their self-renewal suggesting that PrPC 
might be a critical survival factor for hematopoietic stem cells [70].  
For those functions ascribed to PrPC on the basis of Prnp0/0 mice, major concerns arise about 
the possibility of a genetic artifact [71].  For example, alleles in linkage disequilibrium with 
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the deleted gene (which is constantly selected for by investigators during breeding) could be 
actually responsible for the described phenotype. Future investigations with Prnp0/0 mice will 
have to face this and other caveats, and devise genetically stringent experiments to assess 
whether the presumed phenotypes are a primary effect of Prnp deletion and how this is related 
to the physiological function of PrPC. 
 
Prions and the immune system: A fatal tête à tête 
Although prion diseases are neurodegenerative disorders it has been established already a 
long time ago that infectious prions do not only accumulate in the CNS but can also colonize 
extraneural organs of infected individuals. Interestingly, in contrast to the central nervous 
tissue prions are not believed to induce tissue damage in secondary lymphoid organs, 
although some prion related aberrations were reported [72].  
It was already shown in the early days of prion immunology that upon peripheral prion 
exposure secondary lymphoid organs appear to play an important role in the development of 
prion disease: genetic asplenia or splenectomy of mice prior or after peripheral prion 
challenge prolongs the life span of scrapie-infected mice. In contrast, thymectomy or genetic 
athymia had no significant effect [73] suggesting a dispensable role for T-lymphocytes in 
prion pathogenesis. Further experiments investigated the cascade of events upon prion 
exposure in more detail: splenectomy after intraperitoneal (i.p.) prion inoculation revealed 
that peripheral prion pathogenesis becomes independent of the spleen once prions have 
reached the spinal cord [74]. However, a splenic replication phase is not obligatory in all 
rodent TSE models and might be strain-dependent [43,75]. For example Tateishi and 
coworkers have found no effect of splenectomy on incubation times for the Fukuoka 1 strain, 
a mouse-adapted CJD prion [76,77]. This is one of several hints that different prion strains 
appear to differ in their tissue tropisms: they are either lymphotropic, indicating that they 
colonize lymphoid organs right after peripheral infection before invading the CNS, or 
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neurotrophic - meaning that they can invade the brain without replicating in the LRS 
[41,43,44].  
Before the invention of fluorescence-activated cell sorting, the cellular distribution of prions 
in the LRS was studied by separation of splenocytes into various subpopulations based on 
buoyant density of different adherence of cells to plastic surface [78]. In these early 
experiments, it was reported that cells with relatively high specific infectivity had a density 
characteristic of lymphoblasts, myeloblasts and macrophages. Enrichment of macrophages did 
not enhance scrapie infectivity. Already in these (relatively crude) fractionation attempts it 
became clear that the stromal compartment contained ~10 times more prion infectivity than 
the pulp [79]. Sublethal doses of gamma irradiation, which affect mitotically active cells of 
hematopoietic origin but not resident post-mitotic cells, failed to alter the incubation period of 
the disease [80]. These findings suggested that scrapie replication or accumulation in the LRS 
largely depends on radioresistant, post-mitotic cells localized within the stromal compartment. 
However, these experiments did not address the exact cellular and molecular preconditions 
needed for efficient prion transport from the site of entry (e.g. gut) to the LRS and prion 
invasion into the CNS. 
 
Neuroinvasion proper 
The use of Prnp0/0 mice [54] and of bone marrow reconstitution as a technique to generate 
chimeric mice with stromal and hematopoietic compartments of different genotypes revealed 
a first surprise: PrPC itself is involved in transporting prion infectivity from peripheral sites to 
the CNS. Titration experiments indicated that adoptive transfer with wt bone marrow into 
Prnp0/0 mice reconstitutes the capability of the spleen to accumulate prions of the mouse-
adapted Rocky Mountain Laboratory (RML) scrapie strain [81-83]. These results were taken 
to suggest that PrPC expressing hematopoietic cells transport prions from the entry site to the 
LRS, where prions are efficiently replicated. However, the elemental compartment for prion 
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neuroinvasion appears to be non-hematopoietic, since it cannot be adopted by bone marrow 
reconstitution [81,82,84].  
In conclusion, after peripheral exposure - may this be by ingestion or by peripheral infection - 
prion pathogenesis can be regarded as a dynamic process that can be split spatially and 
temporally [3]: (1) infection and peripheral prion replication, (2) prion neuroinvasion and (3) 
progressive, fatal neurodegeneration.  
But what are the exact cellular and molecular mechanisms underlying those three major 
stages? Astoundingly, B-lymphocytes were demonstrated to be of crucial importance for 
prion accumulation in the LRS as well as for neuroinvasion [84]. However, PrPC expression 
on B-lymphocytes is not required [85,86]. This combined with the fact that a stromal 
compartment was hypothesized to be the essential mediator of neuroinvasion, indicated that 
B-lymphocytes themselves are unlike to represent a major replicative unit for prions. Instead, 
B-lymphocyte involvement in peripheral pathogenesis was believed to be indirect, such as 
supporting the development or maintenance of a prion replicating cell type that should express 
PrPC, be - most likely - of stromal origin and in close proximity to B-lymphocytes.  
 
FDCs: Cells with the license to replicate prions 
The cell fulfilling these criteria the most was the FDC. FDCs accumulate PrPSc following 
scrapie infection [87], express high levels of PrPC and are localized in close proximity to B-
lymphocytes within splenic and lymph nodal B-cell follicles. Interestingly, FDC development 
and maintenance was demonstrated to depend on tumor necrosis factor (TNF) superfamily 
members lymphotoxin  and  (LT and LT), which are cytokines mainly produced by B-
lymphocytes, T-lymphocytes and NK cells [88].   
Indeed, blockade of LT signaling by administration of a soluble LT receptor protein fused to 
a Fc portion (LTR-Ig) ablates mature FDCs and significantly impairs peripheral prion 
pathogenesis [89]. In line, mice deficient in LT signaling (lt-/- or ltr-/- mice) are largely 
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resistant to peripherally administered prions [84]. These data for the first time directly 
identified a cell type to be involved in peripheral prion pathogenesis in vivo.  
FDCs are still poorly described cells, characterized by the expression of Mfge8 [90]. It is 
known that FDCs support the maintenance of the lymphoid microarchitecture, trap immune 
complexes by Fc receptors or by binding opsonized antigens to the CD21/CD35 complement 
receptors. Indeed, various studies have demonstrated that the complement components 
expressed on or bound by FDCs are relevant to prion pathogenesis: Mice genetically 
engineered to lack complement factors [91] or mice depleted of the C3 complement 
component [92] exhibited enhanced resistance to peripheral prion inoculation. Further, 
CD21/35 expressed on FDCs was demonstrated to be involved in targeting prions to FDCs 
and expediting neuroinvasion following peripheral prion exposure [93].  
 
FDCs and peripheral nerves: A long-distance relationship 
It is counterintuitive that FDCs which are sessile cells and of stromal origin, localized in 
germinal centers of the LRS, should be involved in transporting prions to the CNS. It 
therefore became crucial to find the prion entry site to the CNS within secondary lymphoid 
organs. Sympathetic nerves, which innervate lymphoid organs to high degree [94] were 
hypothesized as a possible entry port. Therefore, many independent studies have focused on 
the role of the sympathetic nervous system in neuroinvasion from secondary lymphoid organs 
to the CNS. Indeed, these studies indicated that the autonomic nervous system might be 
responsible for this process [79,95-97]. In line, sympathectomy delays the onset of 
experimental scrapie in mice, while sympathetic hyperinnervation enhances splenic prion 
replication and neuroinvasion upon peripheral exposure [98,99]. This suggested that 
innervation of secondary lymphoid organs might be indeed the rate limiting step to 
neuroinvasion [98].  
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However, there is no direct physical synapse between FDCs localized in germinal centers and 
sympathetic nerve endings [100]. So how do prions march from hot spots of prion replication 
to peripheral nerve endings and how do changes in the relative distance of these two poles 
affect prion neuroinvasion? Experimental evidence pointed to the fact that the distance 
between FDCs and splenic nerves indeed affects the velocity of neuroinvasion [101]. FDC 
positioning was manipulated by ablation of the CXCR5 chemokine receptor, which directs B-
lymphocytes towards specific micro-compartments [102]. In this model the distance between 
germinal center associated FDCs and peripheral nerve endings induced superimposition of 
FDCs and peripheral nerves [101,102]. CXCR5 deficiency did not affect any aspect of prion 
pathogenesis within the CNS. However, although velocity of neuroinvasion was similar in 
CXCR5-/- and wt mice following peripheral administration of high prion titers, delivery of 
smaller titers resulted in a dose dependent increase in incubation periods in wt when 
compared to CXCR5-/- mice. Measurement of the kinetics of prion infectivity titers in the 
thoracic spinal cord showed that increased velocity of prion entry into the CNS of CXCR5-/- 
mice is due to FDCs juxtaposed to highly innervated, splenic arterioles. This was validated by 
the prolongation of incubation periods in CXCR5-/- mice depleted for mature FDCs [101].  
This study also raised the possibility that the spread of infection to peripheral nerves occurs 
more rapidly in lymphoid tissues where FDCs are in near proximity to nerves, such as Peyer’s 
patches [103]. Indeed, it was demonstrated that FDCs are crucial to disease progression for 
only a very short time window after oral scrapie challenge: if FDCs are depleted in this time 
window, mice will not succumb to scrapie [104].  
Although these data have been extremely informative, the exact mechanism of prion transport 
from FDCs to peripheral nerves is unknown. Prions could be (1) transported by various cell 
types leaving germinal centers towards nerve terminals, (2) incorporated by murine budding 
retroviruses, (3) released in FDC-derived exosomes or (4) passively diffuse from the site of 
replication to the site of peripheral innervation. Germinal center B-cells [105] as well as DCs, 
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although previously implicated in direct prion transport to the CNS [106], were so far 
excluded as candidates for the active intrasplenic prion transport [107]. Future experiments 
will have to reveal the exact mechanisms of intrasplenic prion transport, which is still one of 
the key questions in the field of prion immunology.  
 
Prion replication in inflamed organs: A paradigm to study prion replication competence? 
Because lymphoid infectivity is found in most prion diseases (e.g. sCJD; vCJD; scrapie; 
CWD) and proinflammatory cytokines and immune cells are involved in lymphoid prion 
replication [87,89,101,108-110], it was of interest to test whether chronic inflammatory 
conditions affect peripheral prion pathogenesis. Chronic inflammation in non-lymphoid 
organs induced prion replication at sites that were previously believed to be prion-free [26,27] 
including liver, pancreas, kidney or mammary gland. This finding, which was initially 
described in transgenic mice experimentally inoculated with prions, could be reproduced in 
free ranging, naturally infected sheep or experimentally infected whit-tail deer [26,111].  
All of the inflammatory disorders described above shared the presence of extra follicular 
structures, so called tertiary follicles, which invariably contain FDCs. It was therefore 
speculated that prion replication in inflammatory foci depends on FDCs: Indeed, ltr-/- or lt-/- 
mice, which display chronic hepatitis without FDCs, did not replicate prions [27].  
 
LTR signaling: From structure to function 
Hence, from these and other experiments with ltr-/-, lt-/- or lt-/- mice [109] LT signaling 
was regarded as a mere prerequisite for FDC development and maintenance [112] rather than 
directly linked to enabling peripheral prion replication competence.  
However, recently published work of various groups in vitro and in vivo suggested a more 
nuanced situation. While crucially dependent on LT signaling in all conditions investigated, 
extraneuronal prion replication was found to occur in the absence of immunohistochemically 
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recognizable FDCs in various paradigms: These included fibroblast or muscle cell lines as 
well as muscles of a sCJD patient with myositis [24,113-116].  
It was therefore hypothesized that extraneuronal prion replication could potentially take place 
in inflammatory disorders devoid of FDCs. Therefore, we studied prion replication in 
subcutaneous granulomas [117], a very common form of chronic inflammation, expressing 
PrPC and LTR, yet lacking FDCs and Mfge8 expression. After i.p. prion inoculation, Prnp+/+ 
granulomas, but neither Prnp0/0 granulomas nor healthy Prnp+/+ skin, accumulated prion 
infectivity and PrPSc long before clinical disease. Reciprocal bone marrow transfers between 
Prnp+/+ and Prnp0/0 mice revealed that prion accumulation in granulomas depended on PrPC-
expressing stromal cells. We also took into account that infectivity found in granulomas may 
represent “spill-over” from lymphoid organs such as spleen. However, granulomas of 
Prnp+/+Prnp0/0 chimeric mice completely lacked any prion infectivity, although their 
spleens displayed prion infectivity titers similar to those of wt mice [81-83]. Homogenates of 
skin located in immediate vicinity of granulomas lacked prion infectivity in both Prnp+/+ and 
Prnp0/0 mice at subclinical stage, in agreement with a report that skin may contain prions only 
at late stages of disease [118]. These results identified granulomas as previously 
unrecognized, clinically silent reservoirs of prion infectivity. 
Further, the nature of the underlying cell type enabling prion replication in granulomas was 
investigated by flow cytometry. We identified a CD45 negative cell type, expressing high 
levels of PrPC and LTR as well as markers characterizing mesenchymal progenitor cells 
(MPCs) (e.g. platelet derived growth factor receptor  and ). Whether this cell type 
resembles a FDC related stromal cell or even a pre-FDC still remains to be determined.  
Administration of LTR-Ig drastically reduced prion infectivity of granulomas, although no 
significant changes in PrPC expression level or frequency of any of the cell populations 
investigated (e.g. lymphocytes, macrophages, MPCs) could be detected. Therefore, lack of 
prion replication competence in granulomas does not depend on LTR-Ig induced depletion 
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of particular cell populations but is rather related to the depletion of LT signaling itself. This 
is corroborated by the mRNA downregulation of known LT target genes (e.g. CCL2) in 
LTR-Ig treated granulomas [117].  
Therefore, besides being an important prerequisite for maintenance of lymphoid 
microarchitecture and FDC neogenesis, LT signaling is very likely to enable peripheral prion 
replication competence on stromal cell types that are histogenetically different from FDCs. 
These data corroborate previous results that peripheral prion replication can occur in the 
absence of FDCs or PrPC expressing FDCs in vivo [82,109]. Whether these results can also be 
extended to other prion diseased species and different prion strains is not known and should 
be investigated in the future.  
PrpC has been demonstrated to be necessary but not sufficient for peripheral prion replication 
[9], indicating the ultimate requirement of additional factors. Future experiments may show 
whether PrPC expression in combination with LT signaling would enable prion replication 
competence or whether other, yet to be identified, factors are necessary. In addition, it will be 
of highest interest to investigate which LT target genes might be involved in allowing prion 
replication competence and how the accrued knowledge can be translated to understand prion 
replication competence of neurons.  
 
Manipulating the immune system to prevent or treat prion diseases 
Proverbial sturdiness of prions, lack of a beneficial defensive response of hosts upon prion 
infection and limited understanding of the physiological functions of PrPC hamper the 
development of efficient interventional strategies against prion diseases. 
On the other hand, in recent years accrued knowledge about the role of the immune system in 
prion pathogenesis has encouraged investigators to explore the feasibility of various 
interventional strategies against prion diseases [119].  Repeated administration of cytidyl 
guanosyl containing oligodeoxynucleotides (CpG-ODN) - mimicking unmethylated bacterial 
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DNA and stimulating the innate immune system through Toll-like receptor 9 (TLR9) - was 
able to extend the survival of peripherally prion-inoculated mice. This observation suggested 
a potential role of CpG-ODN based regimens in post-exposure prophylaxis against prion 
diseases [120]. However, this finding was difficult to reconcile with the knowledge that 
various types of immune deficiencies confer resistance to peripherally administered prions 
and with the unaltered prion pathogenesis in myd88-/- mice, in which TLR9 signaling is 
impaired [121]. Subsequent investigations showed that repeated CpG-ODN administration 
results in immunosuppression and lymphoid follicle destruction, a fact that could per se well 
explain the alleged antiprion properties of this regimen [122]. 
In 1988 Gabizon et al. found that in vitro exposure of infectious hamster brain homogenate to 
anti-PrP antisera resulted in the reduction of the infectivity titer [123]. Later, anti-PrP 
antibodies proved to efficiently inhibit the formation of protease-resistant PrP in cell-free 
systems [124] and to suppress prion replication in cultured cells [125,126].  
While these data constitute a rational for the development of anti-prions immunotherapy, 
achievement of active immunization against PrP is hampered by essential tolerance of the 
mammalian immune system to PrPC. In an ingenious model, transgenic expression of an 
immunoglobulin μ chain containing the epitope-interacting region of a high-affinity anti-PrP 
antibody circumvented the tolerance and resulted in build-up of anti-PrPC titers and 
prevention of prion pathogenesis upon i.p. prion inoculation [127]. Sigurdsson et al. 
succeeded to induce active immunization in wt mice with recombinant prion protein, 
achieving a modest therapeutic effect [128]. The observation that antibodies generated against 
bacterially expressed PrP often display low affinity towards native cell-surface PrPC [129] 
might explain the limited therapeutic results obtained with this approach. Several others 
studies have shown successful circumvention of immunological tolerance to PrP with 
development of a protective B-cell mediated response against prions, including a recent report 
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of effective mucosal vaccination protecting against oral prion infection through oral 
administration of PrP expressed in an attenuated Salmonella vector [130].  
An obvious and more practical alternative to vaccination aimed at achieving protective anti-
prion immune response is passive immunization. Passive transfer of anti-PrP antibodies 
shortly after peripheral prion inoculation succeeded to delay the onset of prion disease [131]. 
However, no beneficial effect was seen when the antibodies were administered at onset of 
clinical signs, suggesting that passive immunization might be a good candidate for post-
exposure prophylaxis rather than for therapy of TSEs. 
Given the potential of antibodies to interfere with prion pathogenesis it was disappointing that 
intracranial delivery of specific anti-PrP antibodies has resulted in rapid and extensive 
apoptosis in hippocampal and cerebellar neurons [132]. Data in this study suggested that this 
occurs possibly through cross-linking of PrPC, assumed to trigger an abnormal signaling 
pathway [132]. These findings emphasize the need for scrupulous in vivo safety studies before 
the feasibility of prion immununoprophylaxis trials in humans can be considered. 
The relevance of LT signaling in peripheral prion replication has indicated inhibition of this 
pathway as a promising strategy against prion diseases. In particular, treatment with LTR-Ig 
might represent a plausible candidate for early post-exposure prophylaxis, namely iatrogenic 
or occupational exposure (e.g. blood transfusion, medical accidents). Interestingly, LTR-Ig 
(baminercept ) proteins have already entered clinical trials as a treatment for rheumatoid 
arthritis and preliminary results concerning the safety of this drug are encouraging [88]. 
Additionally, other immunosuppressive reagents (e.g. corticosteroids) could be efficiently 
used to prevent peripheral prion accumulation or replication. 
 
Prion diseases: Future perspectives 
The last years of prion research have accumulated an enormous wealth of data widening our 
horizon about how prions accomplish peripheral replication, horizontal transmission and 
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neurodegeneration. Although prion diseases represent the only class of neurodegenerative 
disorders in which scientists have at least a grasp on how neurotoxicity is exerted, our 
knowledge is not sufficient to halt or reverse the pathological process in the brain. On the 
positive side it is worth mentioning that we have started to understand the details of how and 
where prions can be replicated and horizontally transmitted. This should pave the way for 
preventing pandemic outbreaks of known, potentially human pathogenic prion strains (e.g. 
BSE) in the future. However, as prion research has indicated in the past, new prion strains are 
on the rise (e.g. CWD) that potentially might represent a health risk to humans. Therefore, in 
vivo models to identify potentially human pathogenic prion strains are urgently needed. 
Although the BSE crisis has been resolved and the numbers of vCJD cases are decreasing, we 
have little knowledge about the distribution of prion infectivity within the general population 
and for how long this prion infectivity can be conveyed in subclinical carriers leading to 
unprecedented human to human transmissions.                
The above indicates that we are just at the beginning of a journey into the details of the prion 
universe, that will lead us to new surprises, challenges and serendipities in the future - most 
likely also highly useful for understanding other neurodegenerative and infectious disorders.   
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Figure legend 
 
Figure 1: Impact of LTR signaling on peripheral prion replication competence in secondary 
lymphoid organs, chronic lymphocytic inflammation (tertiary lymphoid organs) and 
granulomas. (A) Peripheral prion replication in secondary or tertiary lymphoid organs is 
mainly accomplished by PrPC+/ LTR+/ Mfge8+ FDCs, which can be found in splenic white 
pulp follicles, nodal B-cell follicles or within B-cell clusters of inflammatory foci. In contrast, 
replication of PrPSc and prion infectivity in granulomas can occur in the absence of FDCs and 
is most likely accomplished by mesenchymal progenitor cells (MPCs), which are PrPC+/ 
LTR+/ Mfge8-/ PDGFR +. (B) Block of LTR-signaling by repetitive injections of LTR-
Ig dedifferentiates or depletes FDCs in secondary lymphoid organs and leads to a drastic 
decrease in PrPSc load and prion infectivity. In granulomas, this is different. Block of LTR 
signaling by injection of LTR-Ig does not deplete or dedifferentiate PrPC+ MPCs. Still, prion 
replication competence is abolished by LTR-Ig treatment in granulomas, indicating a 
functional link between LTR-signaling and prion replication competence in PrPC+ MPCs.
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Table 1: List of cultured cells capable of replicating prions. Black rectangles indicate permissiveness of cells or cell lines to replicate a particular prion strain. 
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Comments Ref. 
N1E-115 Mouse Neuroblastoma                  [133] 
C-1300 Mouse Neuroblastoma                  [134] 
N2a Mouse Neuroblastoma                  [134] 
N2a#58 Mouse Subclone of N2a                 N2a overexpressing PrPC [135] 
N2a-PK1 Mouse Subclone of N2a                  [46] 
N2a-R33 Mouse Subclone of N2a                  [116] 
SHSY-5Y Human Neuroblastoma                  [136] 
PC12 Rat Pheochromocytoma                 neuronal differentiation with nerve growth factor [137] 
GT1-1 Mouse Hypothalamic neuronal cells subclon 1                  [138] 
GT1-7 Mouse Hypothalamic neuronal cells subclon 7                  [138] 
SN56 Mouse Hybrid septal neuron/neuroblastoma                  [139] 
CAD-2A2D5 Mouse CNS catecholaminergic cell line                 neuronal differentiation by serum deprivation [116] 
HpL3-7 Mouse Hippocampal cells                  [140] 
CGNov Mouse Cerebellar granule neurons                 from transgenic mouse expressing ovine PrPC [141] 
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NSC Mouse Neural stem cells                  [142] 
SMB Mouse Mesodermal cells                 from scrapie-infected mouse brain [143] 
SMB-PS Mouse Pentosan sulfate-cured SMB                  [144] 
L-fibroblast Mouse Subclone of L929 fibroblast cells                  [145] 
L23 Mouse Subclone of L929 fibroblast cells                  [146] 
L929 Mouse Fibroblast cells                  [147] 
LD9 Mouse Subclone of L929 fibroblast cells                  [116] 
NIH/3T3 Mouse Fibroblast cells                  [147] 
NS1 Mouse Fusing spleen cell with NS1 cell                 spleen cell from scrapie-infected mouse [148] 
Glial cell Rat Glial cells from rat trigeminal ganglion                 ethiylnitrosourea-induced ganglion tumor [149] 
HaB Hamster Non-neuronal hamster brain cells                 spontaneously immortalized cells [150] 
MG20 Mouse Microglial cells                  [151] 
CAS Mouse Cerebellar astrocytes                 from transgenic mouse expressing ovine PrPC [141] 
MSC-80 Mouse Schwann cells                  [152] 
MovS Mouse Schwann-like cells from DRG                 from transgenic mouse expressing ovine PrPC [153] 
MDB Deer Fibroblast-like cells                  [154] 
Rov Rabbit Epithelial RK13                 RK13 cells expressing ovine PrPC [155] 
voRK13 Rabbit Epithelial RK13                 RK13 cells expressing bank vole PrPC [156] 
moRK13 Rabbit Epithelial RK13                 RK13 cells expressing murine PrPC [157] 
N
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C2C12 Mouse Myoblasts                 in co-culture with 22L-infected N2a cells [113] 
Chandler, Compton, RML, 139A, 22L, 22F, ME7 and C506: rodent-adapted scrapie prions  
301C: a mouse-adapted bovine spongiform encephalopathy prion strain 
FU: Fukuoka-1, a mouse-adapted Gerstmann-Sträussler-Schinker disease prion strain 
SY: a mouse-adapted sporadic Creutzfeld-Jakob disease prion strain 
CJD: a patient-derived Creutzfeld-Jakob disease prion isolate 
CWD: chronic wasting disease prion isolate 
PrPC: cellular prion protein  
Nuvolone et al., Figure 1
